Nektar Therapeutics (NKTR)
Nektar Therapeutics is a NASDAQ-listed common stock of a biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system. Its research efforts target autoimmune disorders and other inflammatory conditions, with programs that include NKTR-358, a Treg cell stimulator; PEG-CSF1, a PEG-modified protein designed to influence inflammation-resolution pathways; a TNFR2 agonist asset; and NKTR-255, an IL-15 receptor agonist being developed to support the immune system’s response to cancer. The company also maintains collaboration agreements with Takeda Pharmaceutical, AstraZeneca, UCB Pharma, F. Hoffmann-La Roche, Bausch Health, Pfizer, Biogen, Bristol Myers Squibb, Merck KGaA, and SFJ Pharmaceuticals. Founded in 1990, Nektar Therapeutics is headquartered in San Francisco, California, and operates in the United States and internationally.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-NKTR
|
$43.14
|
-34.2% Downside
|
Overvalued
|
$153.25
|
133.6% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-13.8x
|
3.8x
|
39.3x
|
2.191 B
|
1.597 B
|
6.1%
|
86.3%
|
0.4
|
—
|
129.4%
|
